Drug or treatment

Risankizumab clinical trials

• 14Clinical trials
• 1New in 30 days
• 32Countries

Newest trials

All recruiting trials (14)

• Risankizumab for Refractory Perianal Fistulizing Crohn's Disease

  This study tests whether risankizumab can help people with Crohn’s disease who have draining perianal fistulas not responding to other treatments.

  Recruiting Phase 4 Hyogo Medical University · Nishinomiya and 3 other locations · NCT07872449

• Guselkumab versus risankizumab for moderate-to-severe Crohn's disease

  This comparison tests whether guselkumab or risankizumab works better to reduce intestinal inflammation in people with moderately to severely active Crohn's disease.

  Recruiting at 162 sites Phase 3 Janssen Research & Development, LLC · Dothan, Alabama and 163 other locations · NCT07499232

• How risankizumab moves through the body after IV vs SC dosing in healthy adults

  This study tests how risankizumab behaves in the body after intravenous and subcutaneous doses in healthy adult volunteers.

  Recruiting at 2 sites Phase 1 AbbVie · Anaheim, California and 1 other locations · NCT07466550

• Comparing five advanced treatments for axial spondyloarthritis and psoriatic arthritis

  This project will see how well bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor work for adults with axSpA or PsA who have just started one of these medicines, using medical records and patient surveys.

  Recruiting Adelphi Real World · Bath, Somerset · NCT07166315

• Risankizumab for moderate to severe ulcerative colitis in Japanese adults: change in disease activity

  We will see if risankizumab, given as part of routine care, improves disease activity in Japanese adults with moderate to severe ulcerative colitis.

  Recruiting at 29 sites AbbVie · Nagakute, Aichi-ken and 28 other locations · NCT07136116

• Second-line treatment with upadacitinib or risankizumab for adults with Crohn's disease

  This project will test how well upadacitinib or risankizumab work as second-line treatments for adults with moderate-to-severe Crohn's disease who previously used a TNF inhibitor.

  Recruiting at 25 sites AbbVie · Castellana Grotte, Bari and 24 other locations · NCT07073079

• How risankizumab works in children and teens with ulcerative colitis

  This trial tests risankizumab in children and adolescents with moderate to severe ulcerative colitis to see how the medicine moves through their bodies and whether it is safe and helps their condition.

  Recruiting at 73 sites Phase 3 AbbVie · Phoenix, Arizona and 72 other locations · NCT07071519

• Risankizumab for improving quality of life in adults with moderate-to-severe plaque psoriasis

  See if risankizumab improves quality of life for adults with moderate-to-severe plaque psoriasis treated in routine clinical care.

  Recruiting at 82 sites AbbVie · Calgary, Alberta and 83 other locations · NCT07039110

• Assessing the effects of risankizumab on ulcerative colitis in adults

  This study is testing how well risankizumab works for adults with moderate to severe ulcerative colitis by looking at their progress over a year while they receive the treatment from their doctors.

  Recruiting at 57 sites AbbVie · Heidelberg, Baden-Wurttemberg and 56 other locations · NCT06764706

• Assessing long-term use of Risankizumab for Psoriatic Arthritis

  This study is testing how well Risankizumab works over a long time for adults with psoriatic arthritis who haven't had enough relief from other treatments.

  Recruiting at 131 sites AbbVie · Quilmes, Buenos Aires and 131 other locations · NCT06764693

• Fluorescence imaging of a drug for inflammatory bowel disease

  This study is testing a special version of a drug for inflammatory bowel disease to see how well it targets the right areas in the body and to find the best dose for patients.

  Recruiting Phase 1/2 University Medical Center Groningen · Groningen · NCT06606808

• Assessing the safety and effectiveness of risankizumab and adalimumab in children with juvenile psoriatic arthritis

  This study is testing a new medication called risankizumab to see if it works better and is safer than the standard treatment adalimumab for children with juvenile psoriatic arthritis.

  Recruiting at 34 sites Phase 3 AbbVie · Little Rock, Arkansas and 33 other locations · NCT06100744

• Assessing the effects of risankizumab in children with Crohn's Disease

  This study is testing a new medication called risankizumab to see if it helps children with Crohn's Disease who haven't gotten better with other treatments.

  Recruiting at 79 sites Phase 3 AbbVie · Phoenix, Arizona and 84 other locations · NCT05995353

• Evaluating pregnancy outcomes in women exposed to risankizumab

  This study looks at how pregnancy outcomes differ for women with conditions like psoriasis and Crohn's disease who have used risankizumab compared to those who haven't.

  Recruiting AbbVie · Morrisville, North Carolina and 1 other locations · NCT04846959

Quick answers

How many clinical trials of Risankizumab are recruiting right now?

14, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 32 countries. The most sites are in Germany (7 trials), Italy (7 trials), United States (6 trials), Spain (6 trials), United Kingdom (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 4, Phase 1: 1, Phase 1/2: 1, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →